SpyGlass Pharma Inc. (SGP) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 92% of 52W Range • RSI-14 at 71.4 (OVERBOUGHT (>70))
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SGP currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($27.23) and Max Pain ($34.14) forces dealer call-delta covering toward $35.53.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
SpyGlass Pharma Inc. (SGP) slipped -1.06% to $32.51, trading at 92% of its 52-week range ($17.06 – $33.84). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
SpyGlass Pharma (NasdaqGS:SGP) reported positive 4-year first in human trial data for its Bimatoprost Drug Pad IOL System in open angle glaucoma and ocular hypertension. The lead product showed sustained efficacy over fo
HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups86% of patients remained off all topical IOP-lowering drops90% of patients maintained ≥20/25 best
SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SGP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SGP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SpyGlass Pharma Inc. (SGP) ranks #606 by composite RQD confidence (41/100, grade D-) and #354 by equity capitalization ($1.09B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with SGP at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SGP
ACTIVE
SpyGlass Pharma Inc. | D- | 41/100 | — | — | -35.0% | -1.06% | $1.09B | Benchmark Subject |
| IRMD iRadimed Corporation | C+ | 68/100 | 48.8x | 76.7% | 37.7% | +2.16% | $1.10B | /irmd-vs-sgp → |
| AORT Artivion Inc. | D+ | 54/100 | 117.0x | 64.4% | 4.5% | +2.27% | $1.14B | /aort-vs-sgp → |
| PRCT PROCEPT BioRobotics Corporation | D | 48/100 | — | 63.7% | -35.0% | +0.50% | $1.16B | /prct-vs-sgp → |
| SIBN SI-BONE Inc. | D | 48/100 | — | 79.6% | -10.3% | +2.66% | $1.00B | /sibn-vs-sgp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SpyGlass Pharma Inc. (SGP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$39.9M, operating cash flow of -$32.7M, and free cash flow of -$33.5M (-39.4% YoY). On the balance sheet, SGP closed FY2025 with $115.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$39.9M | -$32.7M | -$33.5M | $115.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$29.2M | -$22.0M | -$24.0M | $23.3M | — |
As of 2026-11-01, SpyGlass Pharma Inc. (NASDAQ: SGP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $32.51 (-1.06% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SGP ranks #606 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), SGP carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRMD (iRadimed Corporation) holds a C+ grade (68/100 RQD, P/E 48.8x, ROIC 37.7%, cap $1.10B) and AORT (Artivion Inc.) posts a D+ grade (54/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
Per SGP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778922), SpyGlass Pharma Inc. generated $0 in revenue, -$39.9M in net income, and -$33.5M in free cash flow against $115.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SGP last traded at $32.51 (-1.06% on volume of 125,374 shares), positioning the stock +19.39% above its 50-day simple moving average ($27.23) and +33.46% above its 200-day simple moving average ($24.36). Across its 52-week range of $17.06 to $33.84, SGP sits at the 92.1% percentile with a 14-day RSI of 71.4 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($28.45 to $36.57).
Why SGP Stock slipped -1.06% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.